FDA Clearance Tracker · P140003-S098
Impella 2.5, Impella CP, Impella CP with SmartAssist
Last checked: Nov 20, 2026Latest source record: Jul 8, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jul 8, 2022
Approved
Time to decision
84 days
Received Apr 15, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140003-S098
- Device name
- Impella 2.5, Impella CP, Impella CP with SmartAssist
- Applicant
- Abiomed, Inc.
- Applicant location
- Danvers, MA
- Received
- Apr 15, 2022
- Decided
- Jul 8, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P140003
Device type
- Device class
- Class III
- Specialty
- Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the updated labeling with the information from the Impella PROTECTED PCI Post-Approval cVAD Registry Study.
Source documents
Other decisions for Abiomed, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252766 · Decided Oct 8, 2025 · 40 days after receipt
Device type: Introducer, Catheter (DYB) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.